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Aims Natriuretic peptides are extensively studied biomarkers for atrial fibrillation (AF) and heart failure (HF). Their role
in the pathogenesis of both diseases is not entirely understood and previous studies several single-nucleotide poly-
morphisms (SNPs) at the NPPA-NPPB locus associated with natriuretic peptides have been identified. We investi-





N-terminal pro B-type natriuretic peptide (NT-proBNP) (N = 6669), B-type natriuretic peptide (BNP) (N = 6674),
and mid-regional pro atrial natriuretic peptide (MR-proANP) (N = 6813) were measured in the FINRISK 1997 co-
hort. N = 30 common SNPs related to NT-proBNP, BNP, and MR-proANP were selected from studies. We per-
formed six Mendelian randomizations for all three natriuretic peptide biomarkers and for both outcomes, AF and
HF, separately. Polygenic risk scores (PRSs) based on multiple SNPs were used as genetic instrumental variable in
Mendelian randomizations. Polygenic risk scores were significantly associated with the three natriuretic peptides.
Polygenic risk scores were not significantly associated with incident AF nor HF. Most cardiovascular risk factors
showed significant confounding percentages, but no association with PRS. A causal relation except for small causal
betas is unlikely.
...................................................................................................................................................................................................
Conclusion In our Mendelian randomization approach, we confirmed an association between common genetic variation at the
NPPA-NPPB locus and natriuretic peptides. A strong causal relationship between natriuretic peptides and incidence
of AF as well as HF at the community-level was ruled out. Therapeutic approaches targeting natriuretic peptides
will therefore very likely work through indirect mechanisms.
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Introduction
Atrial fibrillation (AF) and heart failure (HF) are increasingly common
diseases in older adults. For both conditions, natriuretic peptides as
indicators of cardiac wall stress have remained among the strongest
predictors of incident disease.1 They are responsible for fluid and
blood pressure homeostasis through diuretic and vasodilatory effects
and further affect cardiovascular remodelling. In the context of AF
and HF, atrial natriuretic peptide (ANP) and B-type natriuretic pep-
tide (BNP) including their pro-hormones are the most extensively
studied natriuretic peptides. Both are increased in HF with preserved
and reduced ejection fraction. In HF with reduced ejection fraction,
N-terminal pro B-type natriuretic peptide (NT-proBNP) concentra-
tions were higher in individuals with concomitant AF indicating an ad-
ditional AF-related component of NT-proBNP.2 In AF, elevated
natriuretic peptides reflect increased left atrial pressure and adverse
remodelling.3 Restoration of sinus rhythm goes along with decreasing
concentrations.4 Furthermore, the most prominent risk factors for
AF development such as age, sex, increased body mass index (BMI),
hypertension, and HF, have all been related to elevated natriuretic
peptide concentrations.
Even though natriuretic peptides have been extensively investi-
gated as biomarkers for HF and AF, their role and possible contribu-
tion in the pathogenesis of the diseases is not entirely clear. The
temporal relationship of natriuretic peptide elevation and disease on-
set has not been elucidated. Subclinical HF may be associated with al-
ready elevated blood biomarkers and similarly, intermittent, but
undiagnosed AF may result in increased natriuretic peptide concen-
trations due to reverse causation. Furthermore, it is not certain, if the
associations between ANP and BNP/NT-proBNP to AF and HF are
identical.
While the structure of ANP is conserved among species, the pri-
mary BNP structure varies considerably and recent genome-wide as-
sociation studies have revealed and validated several single-
nucleotide polymorphisms (SNPs) in the NPPA-NPPB locus.
Considering the inherently unidirectional association from genetics
to biomarker concentrations, genetics may help to provide some evi-
dence on potential causal relations at the population level.
Therefore, we examined common polymorphisms in the genes of
the two protagonist natriuretic peptides, BNP and ANP and circulat-
ing pro-hormone NT-proBNP concentrations and their association
with incident AF and HF. By using Mendelian randomization, we in-
vestigated the causal relationship between natriuretic peptides and
AF as well as HF.
Methods
Study population
Analyses were performed in individuals from the FINRISK 1997 cohort.
The National FINRISK study enrolls individuals of five Finnish areas every
5 years. A detailed description of the study design has been published
before (http://www.thl.fi/publications/morgam/cohorts/full/finland/fin-fina.
htm).
On enrolment, participants underwent physical examination, filled in a
questionnaire and provided blood samples. Systolic blood pressure and
BMI were measured during the examination. The remaining covariates
and known confounders (current smoking, antihypertensive treatment,
and prevalent diabetes) were by participant history or by history and
prior discharge code (prevalent AF, prevalent HF, and prevalent myocar-
dial infarction). Total cholesterol and creatinine were measured by
routine methods. The estimated glomerular filtration rate (eGFR) was
calculated using the CKD-EPI formula. For follow-up, the National
Hospital Discharge Register, the National Causes of Death Register, the
National Drug Reimbursement Register, and discharge registries of spe-
cialized ambulatory clinics were used to generate information on AF and
HF outcomes either as primary disease or comorbidity.
For our analyses, we excluded all individuals with pre-existing AF
(N = 165, 2.0%) and/or HF (N = 159, 1.9%). Furthermore, participants
with missing covariates and/or genetic data were excluded. The number
of individuals included in the analyses was initially N = 8446, but after ex-
clusion of people with missing natriuretic peptide values there remained
N = 6669 for NT-proBNP, N = 6674 for BNP, N = 6813 for mid-regional
pro atrial natriuretic peptide (MR-proANP). Last follow-up was obtained
31 December 2016.
The FINRISK cohorts were approved by the respective institutional
review boards. The study is in accordance with the declaration of
Helsinki. All participants provided informed consent.
Natriuretic peptide measurements
We measured BNP (BNP, UniProt acc. P16860, residues 103–134),
Roche Elecsys 2010 proBNP (NT-proBNP, acc. P16860 residues 27–
134), and B.R.A.H.M.S. MR-proANP KRYPTOR (MR-proANP, acc.
P01160) in the MORGAM Biomarker Laboratory, University of Mainz,
Germany, using the Abbott Architect i2000. Inter-/intra-assay coefficients
of variation have been reported (http://biomarcare.eu/) as follows: BNP
2.11%/4.28%, NT-proBNP 2.58%/1.38%, and MR-proANP 3.65%/2.33%.
Genotyping and imputation
The samples were genotyped using genotyping array Illumina
OmniExpress, Illumina CoreExome, Affymetrix 6.0, Illumina 610K.
Imputation reference panel was SISu v2 with 2690 hcWGS and 5092
WES Finnish genomes. Pre-imputation quality control was done per gen-
otyping batch. Population outliers were removed based on principal com-
ponents. Pre-phasing done with Eagle 2.3. Imputation with Impute2
(version 2.3.1). Post-imputation quality control consisted of checking
chunk integrity (along the chromosome) and minor allele frequency for
imputed variants (compared to the reference panel). Quality control for
the genome-wide association analysis study (GWAS) results comprised
What’s new?
• The natriuretic peptides or their prohormones B-type natriuretic
peptide, N-terminal pro B-type natriuretic peptide, and mid-re-
gional pro atrial natriuretic peptide were significantly associated
with the development of atrial fibrillation (AF) and heart failure
(HF) in a community cohort.
• Polygenic risk scores derived from the genetic loci coding for
the natriuretic peptides were significantly associated with the
respective protein biomarkers, but no association with disease
outcomes was demonstrated.
• Mendelian randomization analyses showed no causal relation-
ship between natriuretic peptides or their prohormones and
AF or HF. The proteins remain strong disease markers.
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removal of SNPs with Hardy–Weinberg equilibrium P-value <_107,
minor allele frequency <5%, and imputation quality (INFO-value) <0.7,
proportion of missings >_2%. Genotyping batch was used as a covariate in
the analyses. Population stratification was controlled by adjusting for the
first 10 principal components. Close relatives (PI_HAT > 0.2) were
excluded from the analyses.
Single-nucleotide selection
Common SNPs were selected from recent genome-wide association
studies.5–7 The published betas were used. We selected N = 30 replicated
SNPs, 27 in relation to NT-proBNP, three for BNP and MR-proANP.
Due to the strong correlation of the prohormone fragment MR-proANP
and ANP, we used SNPs published in relation to ANP. Only independent
SNPs [distance >_500 kbp or low linkage disequilibrium (correlation
<_0.8)] that reached genome-wide significance were selected. Dependent
SNPs were removed one-by-one (based on effect size) until a set of only
independent SNPs remained. For NT-proBNP, 27 SNPs were used, for
both BNP and MR-proANP, three SNPs each. Details of the SNP selec-
tion and beta coefficients are outlined in the Supplementary material
online, Tables S1–S3. In addition, GWAS analyses were performed for
NT-proBNP, BNP, and MR-proANP, which yielded results that were
in-line with the here-used effect sizes and directions.
Statistical methods
We performed six Mendelian randomizations for all three natriuretic
peptide biomarkers and both outcomes, AF and HF separately. The ratio
method of Mendelian randomization was used.8 Polygenic risk scores
(PRSs) based on multiple SNPs were used as genetic instrumental variable
(IV) in Mendelian randomizations. PRS based on multiple SNPs were used
because (i) they generally are related to a stronger association between
IV and biomarker (NT-proBNP, BNP, and MR-proANP) and (ii) including
more SNPs in a PRS improves the normality of the IV. Weighted PRS
were constructed using beta coefficients from published genome-wide
association study results as weights and SNP values were the number of
effect alleles (0, 1, or 2). All PRS were normalized to have zero mean and
unit standard deviation.
Associations between PRSX and incident AF or HF were estimated us-
ing Cox regression (a) and associations between IV and biomarker were
estimated using linear regression (b). An instrumental variable estimate of
the beta coefficient for the causal association between the biomarkers
NT-proBNP, BNP, and MR-proANP and AF or HF was estimated using
the ratio method by dividing the beta coefficient of the Cox regression
(a) by the beta coefficient of the linear regression (b) (Figure 1). The 95%
confidence interval of the causal beta estimate was estimated using boot-
strapping.9 Causal hazard ratios (HRs) were calculated by exponentiation
of the causal beta. Observational HRs for the associations between bio-
markers and AF or HF were estimated using Cox regression and are used
for comparison with the causal HRs from the Mendelian randomization.
A non-causal beta coefficient was calculated by subtracting the causal
beta coefficient from the observational beta coefficient. The causal beta
coefficient and non-causal beta coefficient were also expressed as a per-
centage of observational beta coefficients.
Checking assumptions underlying Mendelian
randomization
The three assumptions of Mendelian randomization were checked8:
Assumption 1, the association of the PRS with the natriuretic peptides; as-
sumption 2, PRS influence on AF or HF only via the natriuretic peptides;
assumption 3, PRS independent of factors that confound the association
between log (X) and AF or HF (where X can be to NT-proBNP, BNP, or
MR-proANP). Further details how the three assumptions were checked
are provided in the Supplementary material online.
Individuals with prevalent AF and/or HF were excluded from all regres-
sions. Bootstrapping estimates were based on 10 000 repetitions. Two-
sided P-values <0.05 were considered significant.
Results
Study population
The mean age of the cohort was 48 years, 50% were men. Further
baseline characteristics of the study cohort are provided in Table 1.
During a mean follow-up of 16.5 years, 757 (9%) developed incident
AF and 519 (6.1%) incident HF, 228 (2.7%) developed both diseases.
Mendelian randomization
For all three natriuretic peptides, a significant association between
PRS and log (natriuretic peptide) (NT-proBNP beta coefficient
0.1745, P < 0.001; BNP beta coefficient 0.1613, P < 0.001; MR-
proANP beta coefficient 0.0670, P < 0.001) in univariable linear
regressions was observed (Table 2).
In univariable Cox regressions, the PRS was not significantly associ-
ated with incident AF or HF (Table 3). For none of the natriuretic
peptides, a significant causal relation with AF or HF was estimated
(Table 4). For comparison, the observational HRs were all highly sig-
nificant and larger (Figure 2 and Table 5). All Mendelian randomization
HRs crossed the one, which indicates that no causal association may
exist. The 95% confidence intervals for the HF HRs were larger com-
pared to AF which is likely due to a smaller number of cases and the
higher HRs.
Assumption checking
F-statistics for the relation between PRS and natriuretic peptide were
all >10 (Supplementary material online, Table S4), indicating that as-
sumption 1 was met. When, for natriuretic peptide X, PRSX is ad-
justed for log (Xiv-free) or log (X), the beta coefficient of PRSX in the
Cox regression with AF or HF as outcomes loses significance
(Table 3). Assumption 2 was not violated.
PRSX
AF or HF
Cox regression AF or HF~PRSX











bcausal = b2/ b1
Figure 1 Illustration of the ratio method in Mendelian randomiza-
tion of natriuretic peptides and AF and HF. Each natriuretic peptide
X has its own PRS, denoted by PRSX. AF, atrial fibrillation; HF, heart
failure; PRS, polygenetic risk score.
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Most cardiovascular risk factors showed significant confounding
percentages, with some exceptions as outlined in Supplementary ma-
terial online, Tables S5–S7. For each possible observed confounder
Q, we assessed violations of assumption 3 by the linear or logistic re-
gression Q  PRSX and checking if the beta coefficients of PRSX in
these regressions were non-significant. Beta coefficients with associ-
ated P-values for X = NT-proBNP, BNP, and MR-proANP are pro-
vided in Supplementary material online, Table S8. We could not show
significant associations. Assumption 3 was not violated.
Discussion
In our Mendelian randomization approach in a prospective commu-
nity study, natriuretic peptides were not directly causally related to
AF or HF incidence. Whereas the known associations of SNPs and
circulating biomarkers with AF and HF outcomes were robust, no as-
sociation with common genetic variation at the NPPA-NPPB locus was
shown. Our observations remained stable after carefully accounting
for known, common AF and HF confounders including age, sex, BMI,
systolic blood pressure, antihypertensive treatment, total choles-
terol, current smoking, diabetes, prevalent myocardial infarction, and
eGFR.
.................................................................................................
Table 2 Univariate linear regressions of PRSX with
log (natriuretic peptide X)
Exposure Beta (SD) P-value
Log (NT-proBNP) 0.1745 (0.0127) <0.001
Log (BNP) 0.1613 (0.0127) <0.001
Log (MR-proANP) 0.0670 (0.0057) <0.001
Provided are betas and SD.
BNP, B-type natriuretic peptide; MR-proANP; Mid-regional pro atrial natriuretic
peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide; SD, standard
deviation.
.................................................................................................




Age (years) 48.6 ± 13.6
Men, N (%) 4253 (50)
Prevalent myocardial infarction, N (%) 181 (2.1)
Cardiovascular risk factors
Body mass index (kg/m2) 26.7 ± 4.6
Systolic blood pressure (mmHg) 136 ± 20
Antihypertensive treatment, N (%) 1103 (13)
Total cholesterol (mmol/L) 5.47 (2.13–13.6)
Current smoking, N (%) 1944 (23)
Diabetes, N (%) 493 (5.8)
Biomarker
Creatinine (mg/dL) 0.90 (0.10–14.9)
Glomerular filtration rate (mL/min/1.73 m2) 89.5 (2.3–244)
BNP (pg/mL) 14.4 (0.1–2106)
NT-proBNP (pg/mL) 44.4 (5.0–9541)
MR-proANP (pmol/L) 43.0 (4.6–1240)
For categorical variables absolute and relative frequencies are given. Continuous
variables are represented as mean ± standard deviation for near to normally dis-
tributed variables or median (range).
BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic




Table 3 Cox regressions for PRSX in relation to AF and HF
AF HF
Beta (P-value) Beta (P-value)
Natriuretic
peptide, X
Unadjusted Adjusted for log (X) Adjusted for
log (Xiv-free)
Unadjusted Adjusted for log (X) Adjusted for
log (Xiv-free)
NT-proBNP 0.005942 (0.8846) 0.1138 (0.009) 0.02589 (0.55) 0.07679 (0.1271) 0.07918 (0.14) 0.11 (0.041)
BNP 0.02353 (0.5616) 0.1131 (0.009) 0.04215 (0.32) 0.06647 (0.1797) 0.06002 (0.26) 0.1053 (0.044)
MR-proANP 0.01275 (0.7572) 0.1468 (<0.001) 0.02836 (0.51) 0.07036 (0.1456) 0.05683 (0.26) 0.0736 (0.14)
Provided are beta coefficients of the PRSX in the Cox regressions AF/HF  PRSX, AF/HF  PRSX þ log (X), and AF/HF  PRSX þ log (Xiv-free).




Table 4 Mendelian Randomization HRs

























Provided are HRs and 95% CIs.
BNP, B-type natriuretic peptide; CI, confidence interval; HR, hazard ratio; MR-
proANP; mid-regional pro atrial natriuretic peptide; NT-proBNP, N-terminal pro
B-type natriuretic peptide.
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Natriuretic peptides play a counter-regulatory role in cardiac
stress mediated through modulation of haemodynamics and benefi-
cial cardiovascular effects on inflammatory activity, proliferation,
hypertrophy, and fibrosis.10 Medical inhibition of the membrane met-
alloproteinase neprilysin increases the concentration of natriuretic
peptides and has proven to reduce cardiovascular outcomes in HF in
combination with angiotensin receptor blockade.11 But the enzyme
has pleiotropic actions and it also increases the concentration of
other endogenous vasoactive peptides such as bradykinin and adre-
nomedullin. Therefore, the modulation of natriuretic peptides may
not be the main mechanism for its beneficial effects. Convincing data
on therapeutic benefits and improved outcomes of increasing natri-
uretic peptide concentrations with natriuretic peptide substitution
have not been shown in clinical trials.12 In this context, our data sup-
port the observation that therapies addressing natriuretic peptides
only may not be efficient.
A prior Mendelian randomization analysis revealed an association
of SNPs in the NPPA-NPPB locus with natriuretic peptides and hyper-
tension,5 one of the strongest risk factors for AF and HF with a high
population attributable risk. In our cohort, the PRS was not related
to blood pressure. Furthermore, genetic variation of rs5068 among
other NPPA-NPPB locus SNPs was associated with a favourable
cardiometabolic profile, lower prevalence of metabolic syndrome
and hypertension, lower blood pressure, and BMI in Whites of
European ancestry and African Americans.13,14 However, common
SNPs at the NPPA-NPPB locus have not yet been shown to be associ-
ated with AF or HF. None of the recent genome-wide association
studies for AF and HF demonstrated strong signals in the NPPA-NPPB
genes.15,16 No association of rs198389, rs5068, and rs198358 with in-
cident HF could be observed in the prospective population-based
EPIC-Norfolk cohort after stratification for hypertension, obesity,
and coronary heart disease.17 For AF common non-synonymous ge-
netic variants within NPPA in two cohorts of European ancestry could
not be demonstrated either. Other SNPs outside the NPPA-NPPB lo-
cus such as a missense variant LC39A8 (rs13107325) on chromo-
some four have been related to NT-proBNP concentrations and
cardiovascular death.7 The association may again be through alter-
nate pathways because the variant has been identified in relation to
blood pressure and BMI.18,19
In accordance, our candidate gene study did not reveal a signifi-
cant association of the selected SNPs with incident AF or HF. Lack
of direct causality of natriuretic peptide concentrations and incident
AF or HF in our examination of common polymorphisms does not
preclude causal mechanisms in rare mutations of the NPPA-NPPB
Figure 2 Comparison of observational HRs, causal HRs, and non-causal HRs. HRs and 95% confidence intervals are provided. The pie charts illus-
trate the percentage of non-causal and causal beta coefficients of the observational beta coefficient. In the AF/MR-proANP case there is a negative
causal beta coefficient. In order to avoid negative percentages or percentages larger than 100, the absolute values of the causal and non-causal beta
coefficients were expressed as a percentage of their sum. AF, atrial fibrillation; BNP, B-type natriuretic peptide; HF, heart failure; HR, hazard ratio; MR-
proANP, mid-regional pro atrial natriuretic peptide.
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locus. For example, a frameshift mutation in the NPPA gene results in
a mutant peptide with normal circulating concentrations with short-
ening of the action potential duration and the effective refractory
period in familial AF.20 Furthermore, there are multiple indirect
causal pathways which involve genetic variation in the genes coding
for the cardiac hormones and may underlie AF and/or HF onset. We
examined eleven classical risk factors which are frequent confound-
ers of the association of natriuretic peptides and incident AF or HF
and share pathophysiological pathways.8 A certain vertical pleiot-
ropy for these risk factors, i.e. downstream risk factors related with
the biomarkers, may exist and improve our understanding of the
pathways from natriuretic peptides to risk factors. Our conclusions
are not changed in the absence of a significant association with our
outcomes of interest.
Limitations
Our analysis was based on incident AF and HF using national
hospital-based databases. However, especially AF is often an outpa-
tient diagnosis and underdiagnosed in asymptomatic patients. Thus,
our results may not be generalizable to all AF cases. Likewise, in our
study population, no distinction was made between HF with pre-
served and reduced ejection fraction, which may have different rela-
tions with natriuretic peptides. Furthermore, progression of both AF
and HF was not studied here and may still be causally related to natri-
uretic peptides. Although we carefully checked for violations of the
assumptions underlying Mendelian randomization, it cannot be
excluded that such violations would have been detected with more
statistical power and/or information on possible confounders that
were not measured. Studies with more power are required to obtain
more precise estimates of the percentage of the association that can
be called causal and more precise assumption validation. The second
and third assumptions of Mendelian randomization, might then also
be tested at the level of individual SNPs and SNPs that violate these
assumptions can then be left out of the genetic risk score. We com-
bined replicated variants into a polygenic risk instrument to increase
power. However, as known for Mendelian randomization studies
using common variants, power was limited for small effects. We cal-
culated that if the causal effect of the natriuretic peptides on the two
examined outcomes were very small, i.e. 10% of the observational
beta estimate, we would have needed up to 800 000 individuals based
on the data in the FINRISK study. Strengths of the study are the
homogenous sample structure, uniform risk factor, confounder, and
outcome ascertainment and the availability of information on all three
commonly measured natriuretic peptide biomarkers.
Conclusion
Based on a Mendelian randomization approach comprising common
genetic variation at the NPPA-NPPB locus and all three commonly
determined natriuretic peptides, we were not able to show a causal
relationship between the peptides to either AF or HF in the commu-
nity. The observed strong associations of the blood biomarkers with
incident disease may be explained by genetic determination of the
cardiac hormones and their relationship with common risk factors of
both diseases such as obesity and hypertension. Therapeutic
approaches targeting natriuretic peptides will therefore very likely
work through indirect mechanisms, in particular AF and HF risk fac-
tor modulation.
Supplementary material
Supplementary material is available at Europace online.
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Table 5 Observational HRs
Atrial fibrillation Heart failure
Exposure HR (95% CI) P-value HR (95% CI) P-value
Log (NT-proBNP) 2.09 (1.94–2.25) <0.001 2.72 (2.48–2.99) <0.001
Log (BNP) 2.36 (2.18–2.57) <0.001 2.53 (2.28–2.80) <0.001
Log (MR-proANP) 5.30 (4.60–6.11) <0.001 6.16 (5.19–7.31) <0.001
Provided are HRs and 95% CIs.
BNP, B-type natriuretic peptide; CI, confidence interval; HR, hazard ratio; MR-proANP, mid-regional pro atrial natriuretic peptide; NT-proBNP, N-terminal pro B-type natri-
uretic peptide.
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